ARGENTA
27.6.2022 09:01:10 CEST | Business Wire | Press release
Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately. To ensure a smooth transition, Paul will work closely with former CFO Chris O’Donnell until late August.
The CFO role is being relocated from New Zealand to London to enable the CEO and CFO to work closely together in the same time zone, and to be closer to customers and new commercial opportunities.
Chris O’Donnell, who has served as Argenta’s CFO since 2018, is supportive of the decision and has decided to stay in New Zealand. He stepped down from his role on June 24 and will stay on until August 26 to support with the transition. Chris has played a leading role in the success and growth of Argenta, providing skilful oversight to key projects including the transition of ownership to KKR and the acquisition of Klifovet.
Paul Fry has extensive financial experience across several industries including biotech, pharmaceuticals, and telecommunications. Prior to joining Argenta, he was Chief Financial Officer of Vectura Group plc, an industry-leading inhaled drug delivery specialist which was listed on the main market of the London Stock Exchange until 2021. In his time with the company, he played an instrumental role in almost doubling its market valuation.
Before Vectura, Paul was Chief Financial Officer of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor (TCR) technology. He also served as Director of Global Finance Operations at Vodafone plc and spent more than 25 years at GSK, where he held several senior leadership roles.
Will Downie, CEO of Argenta, said: “I am delighted to welcome Paul to Argenta. His proven track record and extensive experience, combined with his strategic financial expertise and outstanding leadership qualities, will have a significant impact on the company. I am excited to partner with Paul to help drive long-term growth and scale for the organization.
“I would also like to take this opportunity to express my gratitude to Chris O’Donnell for his commitment, partnership, and financial stewardship in the time we have worked together. Chris has helped to lay the solid foundation that supports the company's ambitious strategy.”
Paul Fry said: “It is an exciting time to enter the animal health industry and I am delighted to be joining Argenta. The company has a unique offering, strong track record and the potential for significant growth for many years to come. I feel privileged to be able to contribute to this and to have the opportunity to serve Argenta’s customers, team members and shareholders.”
Paul holds a degree from Oxford University and is a member of the Chartered Institute of Management Accounts. He is also a Non-executive Director and Chair of the Audit Committee at Avacta plc, an AIM-listed biotech company developing diagnostics and new oncology therapies.
About Argenta
Argenta is the only combined global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) dedicated to animal health. Founded in 2006 in New Zealand, Argenta’s talented, diverse, and committed employees are driven to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States, the United Kingdom, and Germany, Argenta operates from ‘Molecule to Market’ in partnership with its customers to support their R&D, regulatory, clinical research, and manufacturing needs along the veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220626005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom